Navigation Links
US Regulator Sees No Link Between Tamiflu And Japan Deaths

There is no evidence of a link between Tamiflu and the sudden deaths of 12 children in Japan who took the drug, The US Food and Drug Administration has concluded.

Roche, the Swiss pharmaceutical giant which markets the // drug standing in the front line of defense against a bird flu pandemic, agreed to work on changing the drug's labeling to warn of potential dermatological side-effects, reports AFP.

But the powerful US medicines regulator found unanimously that there was no 'causal link between pediatric deaths and neuropsychiatric adverse events and Tamiflu,' an FDA statement said after a hearing of its paediatric safety panel.

Roche said it 'intends to work with the FDA to change the drug's labeling based on adverse skin events that have occurred in a small number of patients, mostly in Japan.'

'We welcome the outcome of the FDA advisory committee and look forward to working with the FDA and other health authorities to extend our knowledge of the use of Tamiflu and its safety profile,' said William Burns, head of Roche's pharma division. 'The positive role of Tamiflu remains unchanged,' he added.

Reports in Japan have said Tamiflu may have been a factor in several suicides by children aged under 16 who took Tamiflu to treat influenza. The FDA has detailed 75 cases of mental and skin disorders worldwide, including 69 in Japan. The European Union's drugs agency has also asked Roche for a safety review into the drug.

Documents posted on the FDA website attributed increased reports of psychiatric disorders among Japanese children who have taken Tamiflu to a variety of probable causes. Those included increased awareness of flu-associated brain disease, increased access to Tamiflu in Japan, and an accompanying focus by the media and health regulators on potential side-effects.

Countries have placed huge orders for Tamiflu to guard against a feared pandemic of flu that could derive from the H5N1 avian influ enza virus.

The strain has killed more than 60 people in Southeast Asia since 2003 and since last month has been found in Europe, Canada and the Middle East.

Japan has become the single-biggest purchaser of Tamiflu. A health ministry report Monday said that in the worst-case scenario of a mass flu outbreak, up to 640,000 people could die in the densely populated country.

Tamiflu was one of eight drugs being reviewed by the FDA committee 12 months after they were approved for use by children.

Roche insisted to the FDA hearing that Tamiflu is safe, and that more than 30 million people worldwide -- including 11.6 million under-16 in Japan and the United States -- have taken the influenza treatment safely since 2001.

Approximately three to five million people worldwide catch flu each year, resulting in 250,000-500,000 deaths, according to statistics from the WHO.
'"/>




Related medicine news :

1. Tumor Suppressor p53s Contradictory Regulatory System
2. A brush with the U.S. Regulators can cost a fortune
3. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
4. Human Complexity Can Be Attributed To Regulatory Sequence
5. Regulators Object Drug Produced from Genetically Engineered Farm Animals
6. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
7. Medtronic’s Insulin Pump Receives Regulatory Approva
8. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
9. Drug Regulators Need To Think In Long-Term, Say Charities
10. Regulatory T-cells – Protector or Cause of Diseases
11. European Regulators Investigate Common Painkiller Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: